Stock Track | Axsome Therapeutics Soars 5.02% as Analyst Cites Optimistic Long-Term Prospects

Stock Track

Feb 22, 2025

Axsome Therapeutics (AXSM) stock surged 5.02% on Friday during the trading session, reflecting investors' optimism about the company's long-term prospects.

Mizuho Securities analyst Graig Suvannavejh maintained a bullish stance on AXSM, reiterating a Buy rating on the stock. The analyst cited strong sales and strategic pipeline developments as key factors driving the optimistic outlook for Axsome Therapeutics.

Suvannavejh highlighted the company's robust commercial execution and potential for further growth, underpinned by its innovative pipeline and strategic initiatives. With a favorable risk/reward profile, the analyst remains confident in Axsome Therapeutics' ability to deliver substantial value for shareholders over the long term.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1167850716"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1167850716\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1167850716?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-22 00:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1167850716","market":"hk","top_or_hot":-1,"title":"Stock Track | Axsome Therapeutics Soars 5.02% as Analyst Cites Optimistic Long-Term Prospects","media":"Stock Track","content":"<p>Axsome Therapeutics (AXSM) stock surged 5.02% on Friday during the trading session, reflecting investors' optimism about the company's long-term prospects.</p>\n\n<p>Mizuho Securities analyst Graig Suvannavejh maintained a bullish stance on AXSM, reiterating a Buy rating on the stock. The analyst cited strong sales and strategic pipeline developments as key factors driving the optimistic outlook for Axsome Therapeutics.</p>\n\n<p>Suvannavejh highlighted the company's robust commercial execution and potential for further growth, underpinned by its innovative pipeline and strategic initiatives. With a favorable risk/reward profile, the analyst remains confident in Axsome Therapeutics' ability to deliver substantial value for shareholders over the long term.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Axsome Therapeutics Soars 5.02% as Analyst Cites Optimistic Long-Term Prospects</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Axsome Therapeutics Soars 5.02% as Analyst Cites Optimistic Long-Term Prospects\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-22 00:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Axsome Therapeutics (AXSM) stock surged 5.02% on Friday during the trading session, reflecting investors' optimism about the company's long-term prospects.</p>\n\n<p>Mizuho Securities analyst Graig Suvannavejh maintained a bullish stance on AXSM, reiterating a Buy rating on the stock. The analyst cited strong sales and strategic pipeline developments as key factors driving the optimistic outlook for Axsome Therapeutics.</p>\n\n<p>Suvannavejh highlighted the company's robust commercial execution and potential for further growth, underpinned by its innovative pipeline and strategic initiatives. With a favorable risk/reward profile, the analyst remains confident in Axsome Therapeutics' ability to deliver substantial value for shareholders over the long term.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AXSM","symbol_name":"Axsome Therapeutics, Inc.","start_time":0,"source_url":"","article_id":"1167850716","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1167850716","pubTimestamp":1740155426,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Axsome Therapeutics  stock surged 5.02% on Friday during the trading session, reflecting investors' optimism about the company's long-term prospects.Mizuho Securities analyst Graig Suvannavejh maintained a bullish stance on AXSM, reiterating a Buy rating on the stock. The analyst cited strong sales and strategic pipeline developments as key factors driving the optimistic outlook for Axsome Therapeutics.Suvannavejh highlighted the company's robust commercial execution and potential for further gr","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AXSM":"Axsome Therapeutics, Inc."},"translate_title":"分析师称长期前景乐观，Axsome Therapeutics股价飙升5.02%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AXSM":1},"content_text":"Axsome Therapeutics (AXSM) stock surged 5.02% on Friday during the trading session, reflecting investors' optimism about the company's long-term prospects.\nMizuho Securities analyst Graig Suvannavejh maintained a bullish stance on AXSM, reiterating a Buy rating on the stock. The analyst cited strong sales and strategic pipeline developments as key factors driving the optimistic outlook for Axsome Therapeutics.\nSuvannavejh highlighted the company's robust commercial execution and potential for further growth, underpinned by its innovative pipeline and strategic initiatives. With a favorable risk/reward profile, the analyst remains confident in Axsome Therapeutics' ability to deliver substantial value for shareholders over the long term.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}